GSK2282512A
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for GSK2282512A, covering 2014-04-03 to 2015-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age [Phase 2]